Previous close | 37.48 |
Open | 37.57 |
Bid | 37.02 x 800 |
Ask | 37.89 x 800 |
Day's range | 36.97 - 37.79 |
52-week range | 18.79 - 43.66 |
Volume | |
Avg. volume | 345,231 |
Market cap | 1.883B |
Beta (5Y monthly) | 1.37 |
PE ratio (TTM) | 119.84 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.64 (1.72%) |
Ex-dividend date | 21 Feb 2024 |
1y target est | N/A |
BRISTOL, Conn., March 20, 2024--Barnes Group Inc. (NYSE: B) today announced it will release first quarter 2024 financial results on Friday, April 26, 2024, before the market opens.
BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world's first fully approved disease-modifying treatment for Alzheimer's disease. According to Eisai's simulation, Leqembi sales will reach JPY 290 billion for their financial year (FY) 2026, which ends in March 2027 and JPY 1.6 trillion in FY2032.
BRISTOL, Conn., March 05, 2024--Barnes Group Inc. (NYSE: B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today announced the planned retirements of Chairman Thomas O. Barnes and Lead Independent Director Mylle H. Mangum, consistent with the Company’s corporate governance retirement policy, effective at the Company’s Annual Meeting of Stockholders in May 2024. Mr. Barnes will become Chairman Emeritus and continue to lead the B